Location | Wavea | Study population | Mean GT/SIb | Reproduction number (R) | 95% CIc | Basic or effective | Case definition | Reference | Year published |
---|---|---|---|---|---|---|---|---|---|
Mexico | 0 | Community | 1.91 | 1.25 | 0.76–1.74 | Basic | Laboratory confirmed illness | [44] | 2011 |
Australia | 1st | Community | 2.8 | 1.50 | 1.50–2.70 | Effective | Laboratory confirmed illness | [45] | 2010 |
Australia | 1st | Community | 2.8 | 1.20 | 1.0–1.4 | Effective | Laboratory confirmed illness | [45] | 2010 |
Australia | 1st | Community | 2.9 | 2.40 | 2.3–2.4 | Effective | Laboratory confirmed illness | [46] | 2009 |
Australia, rural | 1st | Community | 2.9 | 1.28 | 1.26–1.30 | Effective | Laboratory confirmed illness | [47] | 2011 |
Australia, urban | 1st | Community | 2.9 | 1.26 | 1.22–1.30 | Effective | Laboratory confirmed illness | [47] | 2011 |
Canada | 1st | Community | 1.91 | 1.30 | 1.12–1.47 | Basic | Laboratory confirmed illness | [48] | 2010 |
Canada | 1st | Community | 2.78 | 2.21 | 1.98–2.50 | Basic | Laboratory confirmed illness | [49] | 2012 |
Canada | 1st | Community | 3.6 | 1.63 | 1.31–1.96 | Basic | Laboratory confirmed illness | [48] | 2010 |
Canada | 1st | Community | 4.31 | 1.31 | 1.25–1.38 | Basic | Laboratory confirmed illness | [50] | 2010 |
Chile | 1st | Community | 2.5 | 1.80 | 1.6–2.0 | Effective | Unconfirmed emergency room visits | [51] | 2010 |
Chile, central | 1st | Community | 3 | 1.32 | 1.27–1.37 | Effective | Unconfirmed hospitalizations | [52] | 2012 |
Chile, northern | 1st | Community | 3 | 1.19 | 1.13–1.24 | Effective | Unconfirmed hospitalizations | [52] | 2012 |
Chile, southern | 1st | Community | 3 | 1.58 | 1.45–1.72 | Effective | Unconfirmed hospitalizations | [52] | 2012 |
China | 1st | Community | 2.6 | 1.25 | 1.22–1.28 | Effective | Laboratory confirmed illness | [53] | 2012 |
China | 1st | Community | 4.31 | 1.53 | 1.45–1.60 | Basic | Laboratory confirmed illness | [54] | 2012 |
China | 1st | Community | NR | 1.68 | Â | Basic | Laboratory confirmed illness | [55] | 2011 |
Hong Kong | 1st | Community | 3 | 1.70 | 1.6–1.8 | Effective | Laboratory confirmed illness | [56] | 2010 |
Hong Kong | 1st | Community | 3.2 | 1.45 | 1.4–1.5 | Effective | Laboratory confirmed illness | [57] | 2010 |
Israel | 1st | Community | 2.92 | 1.06 | 0.97–1.16 | Effective | Laboratory confirmed illness | [58] | 2011 |
Italy | 1st | Community | 2.6 | 1.30 | 1.23–1.32 | Effective | Unconfirmed illness | [59] | 2012 |
Japan | 1st | School | 1.9 | 2.30 | 2.0–2.6 | Effective | Laboratory confirmed illness | [60] | 2009 |
Japan | 1st | Community | 2.7 | 1.28 | 1.23–1.33 | Effective | Laboratory confirmed illness | [60] | 2009 |
Mexico | 1st | Community | 1.91 | 1.58 | 1.34–2.04 | Basic | Unconfirmed illness | [61] | 2009 |
Mexico | 1st | Community | 1.96 | 1.42 | Â | Basic | Unconfirmed illness | [62] | 2010 |
Mexico | 1st | Community | 2.6 | 1.40 | 1.2–1.9 | Basic | Laboratory confirmed illness | [61] | 2009 |
Mexico | 1st | Community | 2.6 | 1.22 | 1.05–1.60 | Basic | Laboratory confirmed illness | [61] | 2009 |
Mexico | 1st | Community | 3 | 1.80 | 1.78–1.81 | Effective | Unconfirmed illness | [63] | 2011 |
Mexico | 1st | Community | 3 | 1.43 | 1.29–1.57 | Effective | Laboratory confirmed illness | [64] | 2009 |
Mexico | 1st | Community | 3.1 | 2.20 | 2.1–2.4 | Effective | Laboratory confirmed illness | [65] | 2009 |
Mexico | 1st | Community | 3.5 | 2.30 | 2.1–2.5 | Basic | Laboratory confirmed illness | [11] | 2009 |
Mexico | 1st | Community | 3.6 | 1.75 | 1.6–1.9 | Basic | Seeding from Mexico | [66] | 2009 |
Mexico | 1st | Community | 4.1 | 3.10 | 2.9–3.5 | Effective | Laboratory confirmed illness | [65] | 2009 |
Mexico City | 1st | Community | 3 | 1.72 | Â | Basic | Laboratory confirmed illness | [67] | 2009 |
Morocco | 1st | Community | 2.3 | 1.44 | 1.32–1.56 | Basic | Laboratory confirmed illness | [68] | 2012 |
Morocco | 1st | Community | 2.7 | 1.40 | 1.34–1.48 | Basic | Laboratory confirmed illness | [68] | 2012 |
Netherlands | 1st | Community | 3 | 0.50 | Â | Effective | Laboratory confirmed illness | [69] | 2009 |
New Zealand | 1st | Community | 2.7 | 1.25 | 1.07–1.47 | Effective | Laboratory confirmed illness | [70] | 2011 |
New Zealand | 1st | Community | 2.8 | 1.96 | 1.80–2.15 | Effective | Laboratory confirmed illness | [71] | 2009 |
New Zealand | 1st | Community | 2.8 | 1.55 | 1.16–1.86 | Effective | Laboratory confirmed illness; unconfirmed illness | [72] | 2010 |
North America | 1st | Community | 2.7 | 1.3–2.1 |  | Basic | Laboratory confirmed illness | [73] | 2010 |
Peru | 1st | Community | 2.8 | 1.37 | 1.33–1.41 | Effective | Laboratory confirmed illness | [74] | 2009 |
Peru | 1st | Community | 3 | 1.30 | 1.3–1.3 | Effective | Unconfirmed illness | [75] | 2011 |
Peru, Lima | 1st | Community | 3 | 1.70 | 1.6–1.7 | Effective | Unconfirmed illness | [75] | 2011 |
Singapore | 1st | Dance club | 1.91 | 1.9–2.1 |  | Basic | Laboratory confirmed illness | [76] | 2010 |
Singapore | 1st | Military | NR | 1.91 | 1.50–2.36 | Effective | Laboratory confirmed and unconfirmed illness | [77] | 2010 |
South Africa | 1st | Community | 2.3 | 1.43 | 1.38–1.49 | Effective | Laboratory confirmed illness | [78] | 2012 |
South Africa | 1st | Community | 2.78 | 1.47 | 1.30–1.72 | Effective | Laboratory confirmed illness | [78] | 2012 |
South Africa | 1st | Community | 2.78 | 1.42 | 1.20–1.71 | Effective | Laboratory confirmed illness | [78] | 2012 |
Southern Hemisphere | 1st | Community | 1.9 | 1.16–1.53 |  | Effective | Laboratory confirmed illness | [79] | 2010 |
Southern Hemisphere | 1st | Community | 2.60 | 1.33 | 1.28–1.45 | Basic | Laboratory confirmed and unconfirmed illness | [80] | 2011 |
Taiwan | 1st | Community | 1.91 | 1.14 | 1.04–1.25 | Effective | Laboratory confirmed illness | [81] | 2011 |
Taiwan | 1st | Community | NR | 1.16 | 0.98–1.34 | Effective | Serology confirmed infection | [82] | 2011 |
Thailand | 1st | Community | 1.9 | 1.78 | 1.67–1.89 | Basic | Laboratory confirmed illness | [83] | 2009 |
Thailand | 1st | Community | 2.6 | 2.07 | 1.92–2.22 | Basic | Laboratory confirmed illness | [83] | 2009 |
United Kingdom | 1st | School | 2.2 | 1.33 | 1.11–1.56 | Effective | Laboratory confirmed illness | [84] | 2012 |
United Kingdom | 1st | Community | 2.5 | 1.44 | 1.27–1.63 | Effective | Laboratory confirmed illness | [85] | 2009 |
USA | 1st | Community | 2.2 | 1.70 | 1.4–2.1 | Basic | Laboratory confirmed illness | [86] | 2009 |
USA | 1st | Community | 2.6 | 2.20 | 1.4–2.5 | Basic | Laboratory confirmed illness | [86] | 2009 |
USA | 1st | School | 2.7 | 3.30 | 3.0–3.6 | Effective | Unconfirmed illness | [87] | 2009 |
USA | 1st | Community | 3.5 | 1.3–2.0 | 1.0–2.2 | Basic | Laboratory confirmed illness | [11] | 2009 |
USA | 1st | Camp attendees | 7 | 2.20 | 1.4–3.3 | Effective | Unconfirmed illness | [88] | 2011 |
Vietnam | 1st | Community | 1.9 | 1.50 | 1.5–1.6 | Basic | Laboratory confirmed illness | [89] | 2010 |
Vietnam | 1st | Community | 3.6 | 2.00 | 1.9–2.2 | Basic | Laboratory confirmed illness | [89] | 2010 |
worldwide | 1st | Community | 2.67 | 1–2 |  | Effective | Laboratory confirmed illness | [90] | 2011 |
China | 2nd | Community | 4 | 1.66 | 1.27–2.05 | Effective | confirmed hospitalizations | [91] | 2012 |
China | 2nd | Community | 4.3 | 1.70 | 1.4–1.9 | Effective | Laboratory confirmed illness | [92] | 2010 |
France | 2nd | Military | 2.9 | 1.5–1.6 |  | Effective | Unconfirmed illness | [93] | 2012 |
Iran | 2nd | school | NR | 1.28 | 1.05–1.54 | Basic | Unconfirmed illness | [94] | 2012 |
Italy | 2nd | Community | 2.5 | 1.33 | Â | Effective | Unconfirmed illness | [95] | 2011 |
Japan | 2nd | Community | 3 | 1.48 | 1.41–1.56 | Effective | Unconfirmed illness | [96] | 2012 |
Mexico | 2nd | Community | 3 | 1.62 | 1.61–1.63 | Effective | Unconfirmed illness | [63] | 2011 |
Reunion Island | 2nd | Community | 2.8 | 1.26 | 1.08–1.49 | Effective | Unconfirmed illness | [97] | 2010 |
Taiwan | 2nd | Community | 1.91 | 1.02 | 1.01–1.02 | Effective | Laboratory confirmed illness | [81] | 2011 |
Taiwan | 2nd | Community | NR | 1.87 | 1.68–2.06 | Effective | Serology confirmed infection | [82] | 2011 |
United Kingdom | 2nd | Community | 2.5 | 1.30 | 1.2–1.5 | Effective | Laboratory confirmed illness | [98] | 2010 |
Mexico | 3rd | Community | 3 | 1.24 | 1.23–1.24 | Effective | Unconfirmed illness | [63] | 2011 |
various |  | Community | NR | 1.30 | 1.1–1.4 | Effective | Serology confirmed infection | [99] | 2012 |
Median reproduction number for the 2009 pandemic: 1.46; Interquartile range 1.30–1.70 |